Unknown

Dataset Information

0

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.

ABSTRACT:

SUBMITTER: Redjoul R 

PROVIDER: S-EPMC8277189 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.
| S-EPMC8415894 | biostudies-literature
Unknown Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
| S-EPMC8285117 | biostudies-literature
Unknown BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
| S-EPMC8058049 | biostudies-literature
Unknown Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
| S-EPMC8489274 | biostudies-literature
Unknown Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.
| S-EPMC4472330 | biostudies-literature
Unknown Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers.
| S-EPMC8401044 | biostudies-literature
Unknown Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
| S-EPMC8694796 | biostudies-literature
Unknown Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients.
| S-EPMC7686902 | biostudies-literature
Unknown Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.
| S-EPMC4880046 | biostudies-literature
Unknown Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients.
| S-EPMC9293606 | biostudies-literature